Combined LAG-3 and PD-1 blockade is a promising strategy in treating melanoma. Two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic and resectable high-risk melanoma with positive lymph nodes, have been reported in The New England Journal of Medicine and Nature respectively.
Combined LAG-3 and PD-1 blockade is an emerging strategy for the treatment of melanoma. Tawbi et al. and Amaria et al. report in The New England Journal of Medicine and Nature respectively on two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic, and resectable, high-risk, node positive melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据